Altre lingue Cybin Inc.

Azioni

HELP

CA23256X4075

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 21:00:00 13/03/2026			Variaz. 5gg	Var. 1 gen.
4,640 ^USD	-9,55%		-11,62%	-43,28%

12/03	Helus Pharma annuncia la nomina di Jill Conwell a Chief People Officer, con decorrenza dal 12 marzo 2026	CI
06/03	Cybin Inc. - Special Call

Altre lingue

12/03	Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
12/03	Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026
09/03	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
05/03	Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
05/03	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
05/03	Cybin : Helus Pharma Announces Positive Phase 2 Data For Its Novel Serotonergic Agonist in Generalized Anxiety Disorder (GAD)
05/03	Helus Pharma Says It Recorded Positive Phase 2 Results for Anxiety Drug HLP004
05/03	Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder
05/03	Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
24/02	Helus Pharma appoints former Pfizer chief medical officer to board of directors
24/02	Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
24/02	Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee
17/02	Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
17/02	Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder
13/02	HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
13/02	Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
11/02	Helus Pharma nomme Michael Cola au poste de directeur général pour piloter la prochaine phase de développement et d’exécution
11/02	Helus Pharma nombra a Michael Cola como director ejecutivo para liderar su próxima etapa de crecimiento y ejecución
11/02	Helus Pharma ernennt Michael Cola zum Chief Executive Officer für die Leitung der nächsten Skalierungs- und Durchführungsphase
10/02	Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026
10/02	Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
06/01	Cybin : Corporate Presentation January 2026
06/01	Cybin Inc.(NasdaqGM:HELP) added to NASDAQ Composite Index
05/01	Helus Pharma begins Nasdaq trading, advances mental health therapies
05/01	Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma